Loading company…
Montreal-based Ventus Therapeutics develops drugs against biologically validated targets long considered undruggable.
Founded in 2019 and headquartered in Montreal, Canada, Ventus Therapeutics has completed 3 deals. In February 2022 it raised USD 140.00 mn in Series C funding, co-led by SB Investment Advisers and RA Capital. CEO Marcelo Bigal has a history of leadership in the pharmaceutical industry. Its programs include VENT-02, a brain-penetrant NLRP3 inhibitor in Phase 2 trials for Parkinson's disease, and VENT-03, a cGAS inhibitor set to enter Phase 2 for lupus in 2025. Its ReSOLVE platform applies AI, machine learning, protein science and structural biology to small-molecule discovery.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in